secwatch.observer — SEC 8-K summary
======================================

Issuer:     CODEXIS, INC. (CDXS)
CIK:        0001200375
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001200375-23-000009
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Codexis reports FY2022 revenue $138.6M (+32% YoY); net loss $33.6M; provides 2023 guidance $63-68M ex-PAXLOVID
--------------------------------------------------------------------------------

- FY2022 total revenue $138.6M (+32% YoY); ex-PAXLOVID revenue $63.2M (-10% YoY). Net loss $33.6M ($0.51/share) vs $21.3M loss in 2021.
- Q4 2022 revenue $30.4M (+24% YoY); net loss $12.6M ($0.19/share) vs $10.2M loss in Q4 2021.
- 2023 guidance: total revenue $63-68M, product revenue $35-40M (both ex-PAXLOVID); gross margin 68-73%. Cash runway through end 2024.
- Roche exercised ROFN on newly engineered DNA ligase for NGS; interim Phase 1 data for CDX-7108 (EPI) with Nestlé showed improved lipid absorption.
- Upcoming IND filings: Nestlé for PKU (CDX-6114) H2 2023; Nestlé for EPI (CDX-7108) by end 2023; Takeda for Fabry as soon as late 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1200375/000120037523000009/0001200375-23-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1200375/000120037523000009/cdxs-20230223.htm
  HTML page:      https://secwatch.observer/filing/0001200375-23-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer